Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Changes in the Angle of Uterine Flexion as the Bladder Fills

NCT07803627 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-09-15
Last updated
2026-09-03

Condition(s) studied

Uterine Anteflexion

Investigational drug(s) / intervention(s)

Ultrasonography, Pelvic

Ultrasonography, Pelvic: Repeated ultrasound measurements, alternating between volume and angle of flexion, immediately following a hydration protocol and then bladder emptying.

Study summary

The goal of this clinical trial is to evaluate how bladder filling affects the uterine flexion angle in adult nulliparous women with a uterine flexion angle \<90° when the bladder is empty.

The main questions it aims to answer are:

How does the uterine flexion angle change as bladder volume increases? What bladder volume is needed to obtain a uterine flexion angle \>90°?

Participants will:

Drink 600 mL of water following a standardized protocol. Undergo repeated suprapubic ultrasound measurements of bladder volume and uterine flexion angle.

Remain under observation until urination or for a maximum of 4 hours. No comparison group is included in this study.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Adult woman * Nulliparous * Registered with a social security scheme * Uterine flexion angle \< 90°, empty bladder Exclusion Criteria: * Pregnant woman * Woman wishing to become pregnant and currently trying to conceive * Primary amenorrhoea * Menopause * History of surgical termination of pregnancy * History of medical termination of pregnancy * History of hysterectomy * History of conisation * Absence of the uterus * Symptoms of urinary tract infection (gross haematuria, burning on urination, frequent urination) * Under legal guardianship (curatorship, trusteeship)

Primary outcome measure(s)

  • Uterine Flexion Angle Measured at Different Bladder Volumes in Nulliparous Women With an Anteverted Uterus and Baseline Uterine Flexion Angle <90° — 4 hours
    The relationship between bladder volume and the angle of uterine flexion, as determined from repeated ultrasound measurements in the participants.

Trial sites (1)

FacilityCityRegionStatus
Benoit CHIRON Le Relecq-Kerhuon France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07803627 on ClinicalTrials.gov ↗ ← All trials in France